- Conditions
- Advanced Cancer, Metastatic Cancer, Lymphoma, Solid Tumors, Advanced Malignancies
- Interventions
- CPI-613
- Drug
- Lead sponsor
- Cornerstone Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 39 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2016
- U.S. locations
- 3
- States / cities
- Peoria, Arizona • The Bronx, New York • Dallas, Texas
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 505–528
of 3,445
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Diffuse Large B Cell Lymphoma, Lymphoma
- Interventions
- Pembrolizumab
- Drug
- Lead sponsor
- University of Chicago
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 5 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2024
- U.S. locations
- 1
- States / cities
- Chicago, Illinois
- Conditions
- Graft Versus Host Disease, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes
- Interventions
- anti-thymocyte globulin, filgrastim, busulfan, cyclophosphamide, cyclosporine, methylprednisolone, bone marrow ablation with stem cell support, umbilical cord blood transplantation, radiation therapy
- Biological · Drug · Procedure + 1 more
- Lead sponsor
- Roswell Park Cancer Institute
- Other
- Eligibility
- 5 Years to 50 Years
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1997 – 2017
- U.S. locations
- 1
- States / cities
- Buffalo, New York
- Conditions
- Leukemia, Hairy Cell Leukemia, HCL
- Interventions
- Immunotoxin therapy, CAT-8015 Immunotoxin, Biological therapy
- Drug · Procedure
- Lead sponsor
- Cambridge Antibody Technology
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2007
- U.S. locations
- 3
- States / cities
- Stanford, California • Chicago, Illinois • Bethesda, Maryland
- Conditions
- Refractory Acute Lymphoblastic Leukemia, Relapsed Acute Lymphoblastic Leukemia
- Interventions
- Venetoclax, Navitoclax, Dexamethasone, Vincristine, Calaspargase Pegol, Dasatinib, Cytarabine, Blinatumomab, Methotrexate, Mercaptopurine, Cyclophosphamide, Etoposide, Leucovorin, Intrathecal Triples, Pegaspargase, Erwinia asparaginase, Radiation
- Drug · Biological · Radiation
- Lead sponsor
- St. Jude Children's Research Hospital
- Other
- Eligibility
- 4 Years to 30 Years
- Enrollment
- 35 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2027
- U.S. locations
- 2
- States / cities
- New York, New York • Memphis, Tennessee
- Conditions
- Non-Hodgkin's Lymphoma
- Interventions
- CAMPATH (alemtuzumab)
- Drug
- Lead sponsor
- Genzyme, a Sanofi Company
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 49 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2003
- U.S. locations
- 10
- States / cities
- Colorado Springs, Colorado • Ocala, Florida • Park Ridge, Illinois + 7 more
- Conditions
- Relapsed/Refractory Follicular Non-Hodgkin Lymphoma
- Interventions
- Zanubrutinib, Obinutuzumab
- Drug
- Lead sponsor
- BeiGene
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 217 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2024
- U.S. locations
- 4
- States / cities
- Atlanta, Georgia • Chicago, Illinois • Las Vegas, Nevada + 1 more
- Conditions
- Diffuse Large B-Cell Lymphoma (DLBCL)
- Interventions
- Glofitamab, Obinutuzumab, Tocilizumab, Rituximab, Ifosfamide, Carboplatin, Etoposide
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 43 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2025
- U.S. locations
- 9
- States / cities
- Orange, California • Pembroke Pines, Florida • Chicago, Illinois + 6 more
- Conditions
- Relapsed or Refractory Lymphoma
- Interventions
- Itraconazole 200 mg, Fluconazole 400 mg, Rifampin 600 mg, Rabeprazole 40 mg
- Drug
- Lead sponsor
- Hutchmed
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 59 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2022
- U.S. locations
- 1
- States / cities
- Miami, Florida
- Conditions
- Multiple Myeloma
- Interventions
- Phase 1a: CWP232291, Phase 1b: CWP232291, Lenalidomide, Dexamethasone
- Drug
- Lead sponsor
- JW Pharmaceutical
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 25 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2018
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Multiple Myeloma (MM), Lymphoma, Large B-Cell, Diffuse (DLBCL), Lymphoma
- Interventions
- MIK665
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 31 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2019
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- B-cell Malignancies
- Interventions
- AZD5492
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 174 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2029
- U.S. locations
- 10
- States / cities
- La Jolla, California • Boston, Massachusetts • Rochester, Minnesota + 6 more
- Conditions
- Leukemia, Lymphoma
- Interventions
- LMB-2 immunotoxin
- Biological
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- Up to 21 Years
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2004
- U.S. locations
- 5
- States / cities
- Atlanta, Georgia • Baltimore, Maryland • Bethesda, Maryland + 2 more
- Conditions
- Lymphoma, T-Cell, Cutaneous, Lymphoma, T-Cell, Peripheral, Hodgkin Disease, Lymphoma, Large B-Cell, Diffuse
- Interventions
- Romidepsin, Gemcitabine, Oxaliplatin, Dexamethasone, Pegfilgrastim
- Drug
- Lead sponsor
- Washington University School of Medicine
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2020
- U.S. locations
- 2
- States / cities
- Chicago, Illinois • St Louis, Missouri
- Conditions
- Leukemia
- Interventions
- arsenic trioxide
- Drug
- Lead sponsor
- Washington University School of Medicine
- Other
- Eligibility
- Not listed
- Enrollment
- 13 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1998 – 2002
- U.S. locations
- 1
- States / cities
- St Louis, Missouri
- Conditions
- Solid Tumor, Unresectable or Metastatic Melanoma
- Interventions
- CX-072, Ipilimumab
- Drug
- Lead sponsor
- CytomX Therapeutics
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 3 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2020
- U.S. locations
- 14
- States / cities
- Duarte, California • Los Angeles, California • Coeur d'Alene, Idaho + 8 more
- Conditions
- Graft Versus Host Disease, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes
- Interventions
- CD4+CD25+ regulatory T cells, allogeneic hematopoietic stem cell transplantation
- Biological · Procedure
- Lead sponsor
- Masonic Cancer Center, University of Minnesota
- Other
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 3 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2010
- U.S. locations
- 1
- States / cities
- Minneapolis, Minnesota
- Conditions
- B-Cell Lymphoma, Diffuse Large B Cell Lymphoma (DLBCL), Primary Mediastinal Large B-cell Lymphoma (PMBCL), Follicular Lymphoma, Transformed Follicular Lymphoma (tFL), Mantle Cell Lymphoma, Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Richter Transformation, Marginal Zone Lymphoma
- Interventions
- CD19.20.22 CAR T cells, Fludarabine and Cyclophosphamide
- Biological · Drug
- Lead sponsor
- University of Maryland, Baltimore
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 15 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2028
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
- Conditions
- Relapsed Plasmablastic Lymphoma, Refractory Plasmablastic Lymphoma, Anaplastic Lymphoma Kinase Positive Large B-Cell Lymphoma
- Interventions
- Belantamab Mafodotin
- Drug
- Lead sponsor
- Jacob Soumerai, MD
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2024
- U.S. locations
- 3
- States / cities
- Boston, Massachusetts • New York, New York • Houston, Texas
- Conditions
- Recurrent B-Cell Non-Hodgkin Lymphoma, Recurrent Diffuse Large B-Cell Lymphoma, Recurrent Follicular Lymphoma, Recurrent Mantle Cell Lymphoma, Refractory B-Cell Non-Hodgkin Lymphoma, Refractory Diffuse Large B-Cell Lymphoma, Refractory Follicular Lymphoma, Refractory Mantle Cell Lymphoma
- Interventions
- Loncastuximab Tesirine, Bone Marrow Biopsy, Bone Marrow Aspiration
- Biological · Procedure
- Lead sponsor
- University of Washington
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 11 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2026
- U.S. locations
- 1
- States / cities
- Seattle, Washington
- Conditions
- Ewing's Sarcoma, Osteosarcoma, Astrocytoma, Atypical Teratoid/Rhabdoid Tumor, Ependymoma, Germ Cell Tumor, Glioma, Medulloblastoma, Rhabdoid Tumor, Retinoblastoma, Clear Cell Sarcoma, Renal Cell Carcinoma, Wilms Tumor, Hepatoblastoma, Neuroblastoma, Rhabdomyosarcoma
- Interventions
- sirolimus
- Drug
- Lead sponsor
- Emory University
- Other
- Eligibility
- Up to 30 Years
- Enrollment
- 18 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2017
- U.S. locations
- 1
- States / cities
- Atlanta, Georgia
- Conditions
- Pheochromocytoma, Paraganglioma
- Interventions
- Ultratrace Iobenguane I131
- Drug
- Lead sponsor
- Molecular Insight Pharmaceuticals, Inc.
- Industry
- Eligibility
- 12 Years and older
- U.S. locations
- 3
- States / cities
- Iowa City, Iowa • Philadelphia, Pennsylvania • Houston, Texas
- Conditions
- Leukemia, Acute Lymphocytic
- Interventions
- Copanlisib
- Drug
- Lead sponsor
- Dorothy Sipkins, MD, PhD
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 3 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2023
- U.S. locations
- 1
- States / cities
- Durham, North Carolina
- Conditions
- Sarcoma, Osteosarcoma
- Interventions
- Domatinostat, Sirolimus
- Drug
- Lead sponsor
- H. Lee Moffitt Cancer Center and Research Institute
- Other
- Eligibility
- 12 Years to 40 Years
- Enrollment
- 74 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2031
- U.S. locations
- 4
- States / cities
- Tampa, Florida • St Louis, Missouri • The Bronx, New York + 1 more